SMARCA4-deficient tumors are typically high-grade malignancies that predominantly affect the chest, with a mutation rate of approximately 10% in non-small cell lung cancer (NSCLC) (6). This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.